Does HPV vaccination reduce cervical cancer rates?

Does HPV vaccination really prevent cervical cancer?

Yes, and the evidence is now overwhelming. The most direct proof comes from a large Swedish population study that followed 1.7 million women aged 10–30 for 11 years. Among those vaccinated with the quadrivalent HPV vaccine, only 19 developed cervical cancer, compared to 538 in the unvaccinated group — a cumulative incidence of 47 versus 94 per 100,000 women [8]. That translates to an 88% risk reduction for girls vaccinated before age 17 and a 50% reduction for women vaccinated between 17 and 30 [8].

A Scottish study of the bivalent vaccine (which targets HPV types 16 and 18) found even more striking results: no cases of invasive cervical cancer at all among women vaccinated at age 12 or 13, regardless of whether they received one, two, or three doses [3]. For women vaccinated at ages 14–22 with three doses, the incidence was 3.2 per 100,000 person-years versus 8.4 per 100,000 in unvaccinated women — a significant reduction [3]. These two large population-based studies, from different countries and using different vaccines, converge on the same conclusion: HPV vaccination prevents cervical cancer.

How much does vaccination coverage matter?

Coverage rates directly determine how many cancers are prevented. A modeling study for Georgia projected that achieving 90% vaccination coverage could prevent up to 276 cervical cancer cases over the next decade, whereas current coverage of only 38% for the first dose and 26% for the second is far too low [2]. Similarly, a South Korean model estimated that an ideal scenario with 90% vaccination coverage combined with 70% screening could prevent an additional 12% of cases and 7% of deaths beyond screening alone [1].

Herd immunity also plays a role. A mathematical modeling study found that unvaccinated women still benefit from vaccination of others: at 60% coverage (typical in many Western countries), unvaccinated women had 2.2 to 9.2 times higher cervical cancer risk than vaccinated women, depending on the vaccine type and strategy [7]. This means that even those who skip vaccination get some protection, but the vaccinated group gets far more. The takeaway: higher coverage saves more lives, and the benefits extend beyond just those who get the shot.

Does vaccination work alongside screening?

Yes, and combining both is the fastest route to eliminating cervical cancer. A Swedish trial testing concomitant HPV vaccination and HPV screening in 26,125 women found that this dual strategy could reduce high-risk HPV infections by 62–64% in just three years among the 1994–1998 birth cohorts [4]. The South Korean model showed that adding high-coverage vaccination to screening could accelerate elimination — defined as fewer than 4 cases per 100,000 women — from 2044 (with screening alone) to as early as 2034 [1].

However, vaccination alone is not a substitute for screening, especially in older women or those already exposed to HPV. The Japanese data illustrate this: despite having a vaccination program, cervical cancer incidence has been rising in women aged 20–49, partly due to low screening uptake and delayed vaccine introduction [6]. The global burden remains high — 604,000 cases and 342,000 deaths in 2020 — with rates six times higher in low-development countries [5]. Vaccination is most powerful when paired with regular screening, as the two together catch both preventable and early-detectable disease.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2021 to 2025, 4 from 2024 or later, 6 in Q1 journals, collectively cited 1,479 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 62 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions